Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
Holding NBRVF?
Track your performance easily
NBRVF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.13 - $0.15
Previous Close$0.13
Volume2.00
Average Volume (3M)N/A
Market Cap
$3.00
Enterprise Value-$1.64M
Total Cash (Recent Filing)$2.18M
Total Debt (Recent Filing)$540.00K
Price to Earnings (P/E)―
Beta98.73
Next Earnings
Nov 09, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.78
Shares Outstanding3,230,837
10 Day Avg. Volume444
30 Day Avg. VolumeN/A
Standard Deviation33.20
R-Squared0.00018
Alpha8.25
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-0.41
Enterprise Value/Ebitda0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NBRVF FAQ
What was Nabriva Therapeutics’s price range in the past 12 months?
Nabriva Therapeutics lowest stock price was $0.13 and its highest was $0.15 in the past 12 months.
What is Nabriva Therapeutics’s market cap?
Currently, no data Available
When is Nabriva Therapeutics’s upcoming earnings report date?
Nabriva Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is 379 days ago.
How were Nabriva Therapeutics’s earnings last quarter?
Currently, no data Available
Is Nabriva Therapeutics overvalued?
According to Wall Street analysts Nabriva Therapeutics’s price is currently Overvalued.
Does Nabriva Therapeutics pay dividends?
Nabriva Therapeutics does not currently pay dividends.
What is Nabriva Therapeutics’s EPS estimate?
Nabriva Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nabriva Therapeutics have?
Nabriva Therapeutics has 3,230,837 shares outstanding.
What happened to Nabriva Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nabriva Therapeutics?
Among the largest hedge funds holding Nabriva Therapeutics’s share is Aisling Capital Management LP. It holds Nabriva Therapeutics’s shares valued at N/A.
---
Nabriva Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Nabriva Therapeutics
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
---
---